Keloid or Hypertrophic? The Boundary Decides

Two raised scars can look identical and behave nothing alike. The one that stays inside the original wound is hypertrophic; the one that grows past it is a keloid — and that boundary, visible to anyone who looks for it, determines the prognosis, the treatment and the single most important thing not to do.

One Stays Inside The Wound, One Does Not

Both conditions arise from the same failure. Wound healing overshoots, fibroblasts continue depositing collagen past the point at which the wound is closed, and the scar becomes raised, firm and often red. Up to that point the two are indistinguishable, and in the first weeks after an injury nobody can reliably tell you which one you have.

The difference emerges at the margin. A hypertrophic scar stays within the footprint of the original injury — trace the outline of the cut or the burn and the raised tissue sits inside it. A keloid ignores that boundary, extending into skin that was never wounded, often with the claw-like or budding extensions that give the lesion its name.

Time separates them further. Hypertrophic scars typically reach their peak within months and then flatten and soften partially over a year or two, sometimes substantially. Keloids do not regress. They persist indefinitely and frequently continue to enlarge years after the original injury, including from injuries the patient no longer remembers sustaining.

Why This Distinction Changes Everything

The practical consequence sits in one sentence: excising a keloid without adjuvant treatment reliably produces a larger keloid. The excision is itself a wound, made in tissue that has already demonstrated its tendency to overshoot healing, and it is larger than the injury that caused the original lesion.

This is the mechanism behind the most common scar disaster seen in clinic — a patient who had a modest keloid removed, developed a bigger one, had that removed, and now has something substantially worse than what they started with. Each intervention was locally reasonable and the sequence was predictable from the first.

Surgical management of a keloid therefore never stands alone. Where excision is genuinely indicated it is combined with adjuvant therapy — intralesional corticosteroid, prolonged pressure, sometimes adjuvant radiotherapy in a hospital setting — planned in advance rather than added after recurrence. Keloid treatment begins with deciding whether to cut at all.

What Drives A Keloid

Predisposition is largely genetic and frequently familial. Incidence is markedly higher in individuals of African, Chinese and Southeast Asian descent than in those of European descent, and a patient who has formed one keloid should assume they will form another from a comparable injury.

Site matters considerably. The sternum and upper chest, the shoulders and deltoid region, the upper back, the earlobe and the jawline are the classic locations, and they share high resting skin tension or repeated movement. The eyelids, the palms and the soles almost never form keloids, which is informative about the role of mechanical tension.

Anything that prolongs inflammation in a wound increases the risk — infection, a retained foreign body, repeated trauma, or a wound left to heal by secondary intention. This is why acne on the chest and jawline in a predisposed patient is treated urgently rather than tolerated. Keloids and hypertrophic scars are far easier to prevent than to treat.

How Each Is Managed

Intralesional corticosteroid is the mainstay for both, injected directly into the scar at intervals of several weeks to suppress fibroblast activity and soften the lesion. In resistant keloids it is frequently combined with 5-fluorouracil, which addresses the fibroblast proliferation from a different direction and reduces the atrophy and telangiectasia that repeated steroid alone can produce.

Silicone sheeting or gel, used consistently over months, improves hydration and occlusion of the scar and has a genuine if modest effect — its value lies in duration of use rather than intensity. Pressure therapy is well established for hypertrophic scars, particularly post-burn and after ear surgery, where custom pressure earrings are effective.

Energy-based treatment addresses the components that steroid does not. A vascular laser targets the dense capillary network in an active red scar, reducing both the colour and, by reducing the vascular supply, the growth drive. Fractional resurfacing improves texture in a flattened mature scar. Neither substitutes for the injections in an active keloid.

Earlobes, Chests And Acne Keloids

Earlobe keloids after piercing are among the commonest presentations and among the most treatable, because the site tolerates both excision and sustained post-operative pressure. Excision followed by pressure earrings and a planned course of intralesional steroid has a considerably better record than excision alone.

Chest and shoulder keloids are the difficult ones. Skin tension across the sternum is high and constant, the site moves with every breath, and pressure therapy is impractical. Expectations here are managed carefully: flattening, softening and symptomatic relief from itch and tenderness are realistic goals; disappearance is not.

Acne keloidalis and keloids arising from chest and back acne deserve particular urgency, because the acne is still generating new lesions and each one is a new opportunity for keloid formation. Treating the scars while the acne continues is a losing position — controlling the acne comes first.

Symptoms Matter As Much As Appearance

Keloids itch, sting and hurt. The itch in particular can be severe and is often what actually drives a patient to seek help, rather than the appearance. Pain on pressure is common over the sternum, and clothing catching on a raised scar is a daily irritation that patients tend not to mention unless asked.

These symptoms are a useful marker of activity. A keloid that itches and is deep red is metabolically active and growing; one that is pale, soft and asymptomatic has usually stabilised. Treatment decisions follow that distinction, and symptomatic improvement often arrives well before visible flattening.

It is also worth saying plainly that symptom relief is a legitimate goal on its own. A scar that no longer itches, no longer hurts and has stopped enlarging is a successful outcome even where it remains visible, and treating for that goal is more honest than treating towards an appearance that cannot be achieved.

Realistic Expectations And When To Refer

Hypertrophic scars generally respond well. With appropriate treatment and time they flatten substantially, soften, and lose their colour, and many settle to a pale flat line. The prognosis is good and the honest advice is frequently to combine modest intervention with patience.

Keloids are controlled rather than cured. Recurrence is a genuine risk after any intervention, follow-up runs for years rather than months, and a lesion that has flattened is monitored rather than discharged. A clinic promising elimination of a keloid has either misclassified it or has not followed the patient long enough.

Large, aggressive or repeatedly recurrent keloids belong in a hospital setting where adjuvant radiotherapy and reconstructive surgery are available, and saying so is part of a proper assessment. Where a scar is mature, flat and a problem of texture and colour rather than bulk, scar reconstruction and surgical scar revision become the relevant conversation instead.